Search Saint Luke's
Filters
Showing 1091 - 1100 out of 1384 results
Clinical Trials
IZABRIGHT-Breast01
Breast Cancer
A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment
Clinical Trials
Merck MK2870-010 (TROFUSE 10)
Breast Cancer
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Clinical Trials
Pfizer C4551002 Katsis-1
Breast Cancer
An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
Clinical Trials
Physical Activity in MBC
Breast Cancer
The effect of regular physical activity and virtual exercise intervention on physical functions, fatigue, mental health, and disease progression in Metastatic Breast Cancer (MBC)
Clinical Trials
RASolute
Pancreatic Cancer
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Clinical Trials
Symbiotic-GI-13
Liver Cancer
An Interventional Open-label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
Clinical Trials
Vanguard
Cancer Screening
The Vanguard Study: Testing a New Way to Screen for Cancer
Clinical Trials
Viktoria2 Celcuity
Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer
Provider Search Results
Find expert, patient-centered care with Saint Luke's trusted providers. Search now to connect with nationally recognized, compassionate healthcare teams.
News
The Trenton Telegraph: Why Heart Health Matters–Especially For Women
Tracy Stevens, MD, cardiologist and Medical Director of